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The formulation of drug compounds into nanoparticles has many potential advantages in enhancing
bioavailability and improving therapeutic efficacy. However, few drug molecules will assemble into
stable, well-defined nanoparticulate structures. Amphiphilic polymer coatings are able to stabilise
nanoparticles, imparting defined surface properties for many possible drug delivery applications. In the
present article we explore, both experimentally and in silico, a potential methodology to coat drug
nanoparticles with an amphiphilic co-polymer. Monomethoxy polyethylene glycol–polycaprolactone
(mPEG-b-PCL) diblock copolymers with different mPEG lengths (Mw 350, 550, 750 and 2000), designed
to give different levels of colloidal stability, were used to coat the surface of indomethacin nanoparticles.
Polymer coating was achieved by a flow nanoprecipitation method that demonstrated excellent batch-
to-batch reproducibility and resulted in nanoparticles with high drug loadings (up to 78%). At the same
time, in order to understand this modified nanoprecipitation method at an atomistic level, large-scale all-
atom molecular dynamics simulations were performed in parallel using the GROMOS53a6 forcefield
parameters. It was observed that the mPEG-b-PCL chains act synergistically with the acetone molecules
to dissolve the indomethacin nanoparticle while after the removal of the acetone molecules (mimicking
the evaporation of the organic solvent) a polymer–drug nanoparticle was formed (yield 99%). This work
could facilitate the development of more efficient methodologies for producing nanoparticles of
hydrophobic drugs coated with amphiphilic polymers. The atomistic insight from the MD simulations in
tandem with the data from the drug encapsulation experiments thus leads the way to
a nanoformulation-by-design approach for therapeutic nanoparticles.Introduction
An ideal drug delivery system (DDS) is non-toxic, biodegradable
and biocompatible,1 it should be able to encapsulate sufficient
amounts of drug to provide a therapeutic action, which can be
released at its target site.2 From a practical perspective, it has to
be cheap, easy to manufacture, and stable prior to its admin-
istration. One of the main DDSs that have attracted a lot of
interest in the pharmaceutical eld are nanoparticles (NPs).
NPs, usually in the range of 10–500 nm in diameter, can be
modied according to their physical properties, theiram, Nottingham, NG7 2RD, UK
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f Chemistry 2020composition, surface chemistry and target ligands for speci-
city.3 This exibility allows the design of sophisticated, cost-
friendly and multifunctional NPs. Nanoparticulate DDSs have
many potential applications in a wide range of formulations
including targeted delivery of hydrophobic drugs via parenteral
routes,4,5 and delivery to particular sites e.g. lung.6,7
Polymer-based DDS, and in particular those based on
amphiphilic block copolymers that consist of a hydrophilic
block and a hydrophobic block and can self-assemble when in
aqueous medium,8–10 have attracted a lot of attention. One
example of such amphiphilic polymers are the monomethoxy
poly(ethylene glycol)-b-polycaprolactone (mPEG-b-PCL) diblock
copolymers.11–17 Both mPEG and PCL are polymers that are well-
tolerated by humans and approved by the Food and Drug
Administration (FDA) for DDS. PEG is amphiphilic, soluble in
organic solvents, has a good toxicity prole, is industrially
available at a low cost18 and has been used extensively in DDS.
PCL is a biocompatible, hydrophobic polymer of semicrystalline
nature. The presence of the ester groups in the polymer back-
bone makes it biodegradable as they can be cleaved usually by
























































































View Article Onlinedegradation behaviour can also be controlled via the length of
the PCL block.20 Co-polymers based on mPEG-b-PCL can be
synthesised via ring opening polymerisation (ROP); themPEG is
themacroinitiator and the catalysts are Lewis acidmetal centres
such as stannous octanoate,11,21 or calcium ammoniate12 or
organic catalysts including 1,5,7-triazabicyclo[4.4.0]dec-5-ene
(TBD).22 Consequently, mPEG-b-PCL polymers have already
been investigated for the delivery and controlled release of
many drugs, including anti-cancer drugs23,24 and, of particular
interest to us here, the nonsteroidal anti-inammatory drug
(NSAID) indomethacin.16,25,26
Indomethacin has low aqueous solubility (0.937 mg L1 at
25 C 27), a property shared by an estimated 40% of existing
active pharmaceutical ingredients (APIs) and 70–90% of the new
candidate APIs.28,29 This low water solubility leads to poor
bioavailability30 and can result in uncontrollable precipitation
aer dosing.31 In order to improve formulation performance
and to achieve a high surface area to volume ratio, particle size
reduction, either via top-down or bottom-up methods, has been
established in the pharmaceutical industry as a common
formulation strategy.32,33 However, production of pure drug
nanoparticles can be difficult to achieve and usually results in
the rapid aggregation of the nanoparticles back into larger
particles unless the particles are stabilised, typically by surfac-
tants, or via other interactions.34
An alternative strategy is to incorporate the API into more
complex nanoparticulates which can subsequently release the
drug. Onemethod to produce polymer-based drug bearing NPs is
via nanoprecipitation,33,35,36 also known as “co-solvent” or inter-
facial deposition method.9 In nanoprecipitation, two solvent
phases are required; an organic phase where the amphiphilic
polymers and the API are dissolved and an anti-solvent medium
where the polymers are insoluble (in most cases this means
water). The organic phase is added in the anti-solvent, either by
a drop method37,38 or by pumping the two solvent streams in
amixer (ash nanoprecipitation FNP33,39,40). Bothmethods lead to
the formation of the polymeric NPs due to polymer chain collapse
via hydrophobic chain–chain association. During this process,
drug molecules in the vicinity can be encapsulated into the
polymer matrix, forming the nal polymer–drug NPs. mPEG-b-
PCL indomethacin loaded NPs have been produced in the past
via a drop-nanoprecipitation method with the highest drug
loadings reported ranging between 16–42%.10,16,25,41
Tuning the parameters to maximise the efficiency of such NP
preparationmethods is not trivial. In order to investigate factors
like polymer lengths, solvent selection, mixing times, mixer
geometries, as well as more fundamental issues like polymer–
drug interactions, a variety of computational methods such as
computational uid dynamics (CFD) and molecular dynamics
(MD)42–46 have previously been applied. MD in particular has
been used to calculate solubility parameters,47–49 polymer–drug
encapsulation46,50 and polymer self-assembly.43,51–54 Through
such studies, MD has provided invaluable insight into the
interactions that take place at an atomic level, and so link
fundamental principles of physics and chemistry to the emer-
gent behaviour of these complex systems. To date however,
nanoprecipitation in particular has been modelled most usually19522 | RSC Adv., 2020, 10, 19521–19533using lower resolution computational methods, due to the large
size of the systems to be simulated, and long timescales
required; dissipative particle dynamics34,55 is a popular
approach. Recently though we have demonstrated the applica-
tion of a multiscale modelling approach, where the solutes can
be studied in atomistic detail while the solvent is treated in
a low-resolution manner.46 These studies have proved very
insightful, however a detailed all-atom simulation of nano-
precipitation where all interacting species are modelled at full
resolution is desirable, and so far has been missing from the
eld.
The objective of this work was to develop a method of
encapsulating a drug nanoparticle in a thin polymer layer, to
increase the drug loading while stabilising the drug nano-
particle. The objective also included some understanding of the
mechanism of the encapsulation method through a parallel
investigation using computational modelling. The present work
is based on a similar concept developed in the polymer encap-
sulation of iron oxide nanoparticles using the interfacial
deposition method.56,57 In this prior work,57 iron oxide nano-
particles with a thin layer of polymer surrounding the NP were
generated and we therefore adapted this method for the prep-
aration of hydrophobic drug-containing nanoparticles. We
describe here, the initial stages of this method development to
drug nanoparticles combining both top-down (macro to nano)
and bottom-up (molecular to nano) approaches. The drug
nanoparticles were formed from a top down method, via
a simple sonication in water pre-step, while the polymer coating
was applied by a bottom up method. Ultimately, we demon-
strate here a method that provides excellent batch-to-batch
reproducibility and results in nanoparticles with high drug
loadings (up to 78%). At the same time, computational simu-
lations of the polymer coating procedure using fully atomistic
MD simulations, provides insights into how and why this
nanoparticle production and coating process takes place.Materials and methods
Molecular dynamics methodology
Details of all non-standard data les, input scripts, and simu-
lation protocols is included in the ESI.†System preparation
Models and forceeld parameters for the polymers were devel-
oped as follows. First a “minimal” model for a mPEG-b-PCL
polymer, consisting of one of each of the required start, repeat,
and end units, was created using ChemDraw3D (Fig. 1, B1). This
was then submitted to the online Automated Topology Builder
(ATB) tool58,59 that provided appropriate parameters for use with
the GROMOS53a6 or 54a7 (ref. 60 and 61) force-elds. The
model was then dissected into individual monomer compo-
nents (residue topology les) that could then be reassembled
into polymers of any desired composition/ratio (using the tleap
tool of AMBERtools62). Parameters for indomethacin were also
obtained via the ATB service. All topologies and parameters for
the models used in this work can be found in the ESI.†This journal is © The Royal Society of Chemistry 2020
Fig. 1 (A1) Ring opening polymerisation of 3-CL using monomethoxy
poly(ethylene)glycol as the initiator and TBD as the organic catalyst.
(A2) The interfacial deposition method using two syringe pumps,
where the organic phase containing the polymer is mixing in a T mixer
with the aqueous phase containing just water (polymeric NPs forma-
tion) or water with drug particles (polymer–drug NP formation). (B1)
The polymer residues for the MD simulations (B2) the start of the MD
polymer–drug NP formation simulation, replicating the mixing of the
























































































View Article OnlineThe interfacial deposition method was envisioned as
a biphasic model, where two regions, the organic and the
aqueous, were allowed to mix (Fig. 1, B2). A large cubic box (edge
of 26.7 nm) was built using Packmol63 that contained the
aqueous region. For the coating studies a 5 nm (diameter)
amorphous indomethacin sphere, containing 145molecules, was
placed in the centre of the box. The box was solvated in GRO-
MACS using the gmx solvate tool, using the SPC water model,64
resulting in a 4.12 mg ml1 indomethacin in water suspension.
The box was then expanded in the x direction in such a way to
accommodate the acetone–polymer phase, addressing two crit-
ical parameters: (a) the acetone : water molar fraction (xa ¼
0.089), corresponding to the experimental setup where 2 ml of
acetone are mixed with 5 ml of water and (b) the number of the
polymer chains needed hypothetically to coat all of the particle'
surface, but still at a reasonable polymer : acetone concentration.Running parameters
The GROMOS53a6 forceeld was used for the earlier studies of
polymer equilibration, acetone–water miscibility and initial
biphasic test-studies. With the release of the newest 54a7
forceeld, the latter was selected for all biphasic simulations.60
The cut-off distance for the van der Waals and the electrostatic
interactions was set to 1 nm. All MD simulations were run in
GROMACS (versions 4.6.5 and later 5.1.0)65 using either
resources of the high performance computing (HPC) cluster of
the University of Nottingham or on the UK National Super-
computer ARCHER.66 Visualisation of the trajectories and vis-
ualisations used in this work were performed using VMD.67
Aer the solvation of the biphasic box in GROMACS using the
SPC water model,64 the atoms were relaxed by 10 000 steps of
EM with the steepest descent algorithm. Then each of the two
phases were equilibrated separately, via NVT ensembles at 298
K (V-rescale thermostat) for 100 ps and then in an NPT
ensemble at 1 bar (Berendsen barostat) was applied to the whole
system for another 100 ps. Bonds to hydrogen atoms wereThis journal is © The Royal Society of Chemistry 2020constrained to allow a time step of 2 fs. All of the MD simula-
tions were run with the same barostat and thermostat, under
PBC. Long-range electrostatics were treated with PME68,69 At the
end of each equilibration step (EM, NVT, NPT) of the previous
processes, the potential energies, temperature and pressure
were checked retrospectively to ensure the proper equilibration
of the system.
Analysis of the simulations was achieved using the built-in
GROMACS tools; gmx distance and gmx mindist modules were
used to calculate the distances between the centre of masses,
and the number of contacts, retrospectively, of two groups of
interest. gmx densitywas used to calculate the distribution of the
solvent molecules across a box direction in order to evaluate
whether the two solvents have adequately mixed within the
simulation time. The gmx msdmodule was used to calculate the
diffusion coefficient D of acetone in water. Solvent evaporation
was replicated computationally as follows: from the nal
conguration of the system, a percentage of the acetone mole-
cule were randomly chosen, removed, and replaced with water
molecules (4 waters per acetone molecule). Aer energy mini-
mization 10 ns of MD was run. The process was repeated ve
times, removing 20%, 30%, 40%, 50%, and 50% of the
remaining acetone molecules respectively each cycle.
Experimental materials and methodologies
All chemicals were bought from Sigma Aldrich unless stated
otherwise. Monomethoxy poly(ethylene glycol) (mPEG) with
molecular weights 350, 550, 750, 2000 g mol1, 3-caprolactone
(3-CL) and the catalyst 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD)
were used as received and were kept under nitrogen atmo-
sphere. Dichloromethane (DCM) and chloroform (CHCl3) HPLC
grade were purchased from Fischer Scientic. Indomethacin
(Lot #BCBK0293V) was purchased from Sigma Aldrich and was
used as received.
Polymer synthesis
mPEG-b-PCL copolymers were synthesised via ROP using the
mPEG chains of different molecular weight as the initiators
(Fig. 1A)70 and the organic catalyst 1,5,7-triazabicyclo[4.4.0]dec-
5-ene (TBD).22,71,72 All items of glass equipment (syringes and
round bottom asks) were kept in an oven overnight at 150 C to
remove any residual moisture. Prior to the reaction they were
placed under a fume hood and a magnetic stirrer was added to
the round bottom ask which was quickly capped with a rubber
septum. A constant nitrogen ow was introduced to prevent the
presence of moisture, and the ask was heated to 110 C. The
mPEG was added to the ask, (either with a syringe or prior to
capping) and the system was le under nitrogen for an extra 20
minutes before the addition of the 3-CL. A xed molar ratio of
[mPEG] : [3-CL] [1] : [40] was maintained in all the reactions.
The 3-CL was added drop-wise via a glass syringe and a sample
was collected for the determination of the initial monomer
units via 1H NMR. The reaction started with the addition of the
catalyst (TBD dissolved in DCM, 2%molmol1 with respect to 3-
CL). Maximum conversion to polymer was achieved aer 30
























































































View Article Onlinethe system to air. The result was a very viscous liquid that aer
cooling to room temperature needed to be dissolved in chlo-
roform for the following purication step. The polymers were
puried via precipitation in cold methanol for the removal of
any unreacted monomer and the catalyst.
Polymer characterisation
1H-NMR spectroscopy was used to determine the degree of
polymerisation and the purity of the nal polymers. All NMR
samples were prepared with CDCl3, run in a Bruker DPX Ultra-
Shield spectrometer (400.1 MHz) at 25 C and were analysed with
the MestReNova soware (version 8.0.2) of MestReLab. GPC was
carried out using a PL50+ Polymer Laboratories system,
employing twomixed bed (D) columns at 30 C, using chloroform
(CHCl3) as the mobile phase, ow rate 1 ml min
1 equipped with
a refractive index detector. Polystyrene standards (Mn range:
443 000 to 132 g mol1) were used to calibrate the GPC. Molec-
ular weights and polydispersity (Đ) values were calculated using
Polymer Labs Cirrus 3.0. Water Contact Angle (WCA) measure-
ments were conducted at 25 C using a KSV Cam 200 (KSV
Instruments Ltd., Helsinki, Finland) equipped with a dedicated
soware (CAM200). Samples were prepared by coating glass
microscope slides with polymer thinlms via solvent evaporation
from 5% w/v solutions of polymers in acetone. Attenuated total
reectance infrared spectroscopy (ATR-IR) spectra were recorded
with an Agilent Technologies Cary 630 FTIR equipped with
a diamond single reection ATR unit. Spectra were acquired with
a resolution of 4 cm1, in the range 4000–650 cm1 by recording
32 interferograms. Differential scanning calorimetry (DSC)
(Q2000, TA Instruments, Leatherhead, UK) experiments were
conducted at a heating rate of 10 C min1. Thermal Analysis
Soware (Version 4.5.05A) was used for data analysis.
Preparation of nanoparticles
Unloaded polymer nanoparticles were prepared following an
interfacial deposition method9 previously adapted for the
preparation of polymer coated iron oxide nanoparticles
(IONPs).57 The method is based on solvent displacement and is
schematically described in Fig. 1B. The organic phase was
prepared by adding various amount of polymer (0.1, 0.2, 1, 0.2,
10 and 20 mg) in acetone (2 ml). The acetone–polymer solution
was loaded in a glass syringe and used in the organic phase
pump. In the aqueous phase, freshly ltered HPLC grade water
(5 ml) was used. The volumes of the two phases were kept
constant in all the experiments. The two pumps started the
mixing of the two phases simultaneously (organic phase ow
rate 0.84 ml min1, aqueous phase ow rate 2.4 ml min1). The
solvents were introduced to the connecting tubes (PEEK,
organic solvent resistant, 0.25 mm internal diameter bought
from Kinesis UK) and were mixed using a T-connector (Kinesis).
The mixture was then collected in a vial containing a magnetic
stirrer. The resulting solution was stirred overnight for the
evaporation of acetone and was collected for further analysis.
The drug-bearing aqueous phase was prepared by adding
solid indomethacin into a round bottomed ask containing
50 ml water (HPLC grade, ltered) in order to achieve different19524 | RSC Adv., 2020, 10, 19521–19533theoretical concentrations (1, 0.5, 0.25, 0.1 mg ml1). The ask
was then sonicated for 15 minutes resulting in a milky
suspension which was immediately used in the coating
experiments.
Polymer coated indomethacin nanoparticles were prepared
with the same procedure as the polymer-only nanoparticles; the
organic phase of the acetone–polymer solution (2 ml) and the
drug-bearing aqueous suspension of the freshly sonicated
indomethacin (5 ml) were mixed using the syringe pumps
(organic phase ow rate 0.84 ml min1, drug-bearing aqueous
phase ow rate 2.4 ml min1). Aer the evaporation of acetone
overnight, the resulting nano-suspension was collected and an
extra purication step was introduced to ensure the removal of
any uncoated drug particles; the suspension was centrifuged (3
minutes at 2000 rpm) to sediment the uncoated free drug,
which tended to aggregate. The supernatant containing the
polymer coated drug nanoparticles was collected and was used
either as collected for the size measurements or was lyophilised
for the determination of the drug loading.Nanoparticle characterisation
Nanoparticle size was determined by dynamic light scattering
(DLS) at 25 C, using a Malvern ZetaSizer Nano ZS at a scattering
angle of 173 and laser of 633 nm. All samples were measured in
triplicate for the report of the average values (intensity
distributions).
The critical aggregation concentration above which polymer
chains will collapse to form nanoparticle aggregates was
measured by DLS; a suspension of polymer NPs (1 mgml1) was
diluted in water in a concentration range (300–0.1 ml mL1).
Using the highest concentration (300mgml1) the attenuator of
a Malvern ZetaSizer Nano ZS was selected and kept constant
during the rest of the measurements. The count rate (kcps) was
recorded for each of the decreasing polymer concentrations.
The concentrations were plotted against the count rates.
The colloidal stability of the NP formulations was investi-
gated using increasing salt concentrations. Barium chloride
(BaCl2) in a range of concentrations (0.16–0.66 M) was added to
0.5 ml of the NP suspension and was le for 10 minutes. If
a precipitation of the NPs was observed, then this was consid-
ered to be the maximum salt concentration at which the NPs
were stable.
Zeta potential measurements were conducted at 25 C, using
a Malvern ZetaSizer Nano ZS. The nanoparticle suspensions
were used without any further treatment and were run in trip-
licate for the report of the average values.
Transmission electron microscopy (TEM) was used to char-
acterise the size and morphology of the nanoparticles. The
sample in aqueous suspension (13 ml) was added to a copper
grid (formvar/carbon lm 200 mesh copper (100)) was le on
the grid for 10 minutes and then the excess was removed via
a lter paper. Then, freshly prepared uranyl acetate (2%, 13 ml)
was added on the grid and was le for 5 minutes before the
removal of the excess with a lter paper. The grid was allowed to
dry under a fume hood for a minimum of 30 minutes prior to
























































































View Article OnlinePolarised optical microscopy (POM) was used to validate the
physical state of the NPs. An Advanced Polarising Microscope
(Prior LuxPOL™ with 12 V and 30 W halogen lamp) was used.
The nanosuspensions were added via a pipette on a glass slide
and pictures were collected with and without the polariser.
Quantication of drug loading was achieved via UV-Vis
spectroscopy using an Agilent UV-Vis spectrometer. The cali-
bration curve for indomethacin was prepared in an aceto-
ne : methanol mixture (80 : 20) measuring the absorbance at
350 nm. The lyophilised samples were dissolved in the solvent
mixture and their absorbance was measured. Drug loading and
entrapment efficiency were calculated as follows:
% drug loading ¼ amount of coated drug
mass of NP
 100 (1)
% entrapment efficiency ¼ amount of coated drug
initial amount of drug
 100 (2)
To account for the drug losses that were observed both
during the syringe loading with the indomethacin suspension
and during the experiments (discussed in detail in the Results
section), the latter eqn (2) was modied to the following:
% entrapment efficiency ¼
amount of coated drug
amount of recovered control drug NPs
 100 (3)
Results and discussion
The nanoprecipitation methodology in the presence of nano-
particles can produce either polymer coated nanoparticles, or
a mixture of polymer nanoparticles and drug nanoparticles, so
control experiments were required in both computational and
experimental work to determine which particles are present and
the relative size ranges of the different alternative products.
These were also important in determining whether there is
agreement between the computational and experimental results.
Molecular dynamics simulations
The purpose of our molecular dynamics simulations was to
provide atomic-level insights into the NP formation process.
This was technically challenging due to the complexity and
novelty of the system, from a computational perspective. Firstly,
as the whole NP formation process is driven by the acetone–
water diffusion, selecting the correct acetone model was
required. Despite the existence of the various acetone
models,73–78 modelling acetone–water diffusion has proven to be
challenging and the modelling community still lacks an
adequate acetone model to use in the GROMOS53a6 & 54a7
forceelds.43,61,76,79,80 Aer testing the existing models in trial
systems and following past work from our group,46 it was
decided to use the ATB-derived acetone model, which demon-
strated good miscibility with water (topologies at ESI†).
In order to validate the behaviour of the molecular compo-
nents in this work, it was necessary to perform a series ofThis journal is © The Royal Society of Chemistry 2020control simulations of the polymers and the drug NP in the
presence of pure solvents. In simulations, the mPEG350PCL was
soluble in acetone (ESI Fig. 1†) but formed aggregates in water
(ESI Fig. 2†). The same was observed when an indomethacin NP
of 5 nm diameter was used (ESI Fig. 3 and 4†), thus demon-
strating that the basic physicochemical properties of the poly-
mer and drug components reected experimental conditions.
Experimentally, solvent displacement methods are used
widely to produce drug loaded NPs.20,81,82 In such systems, the
polymer and the drug are dissolved in an organic solvent, which
is thenmixed with water. Themixing of the solvents is performed
either via the drop-by-drop addition of the organic phase into the
water (batch method), or by using mixing of streams of the two
uids (ow method). In both cases, the solvent displacement
causes the hydrophobic part of the polymers to aggregate and
form NPs. Typically, in these systems a large excess of polymer is
used together with dissolved drug, usually resulting in low yields
and encapsulation efficiencies. The system presented in this
work differs from the above in regard to the drug-bearing phase
(which is in nanoparticulate form) and in the relative amount of
polymer (which is much lower relative to the amount of drug).
Indomethacin has a very low aqueous solubility27 so the relative
solubility of the drug in both phases is important to the outcome
and the MD system was designed as a biphasic one (Fig. 1C).
Every attempt was made to match realistic experimental condi-
tions; however, a compromise must be made to ensure that the
system is large enough to be representative, but at the same time
small enough for the simulation to be completed at a reasonable
computational expense. Due to the latter, only the simulations
using mPEG350PCL were carried out.
Firstly, the behaviour of the polymers in this biphasic system
was investigated. As expected from the experimental results,
during simulations the PCL chains start to aggregate, as the
polymers are exposed to more water molecules as they diffuse in
from the aqueous compartment. Due to the continuing pres-
ence of the acetone in the system, the polymer NP has not fully
formed by the end of 100 ns simulation. However, during the
following acetone evaporation simulations, the hydrophobic
PCL blocks of the polymer chains aggregate more rmly,
leading to the formation of a dense polymer NP of 3.4 nm
diameter (Fig. 2 and ESI Fig. 5, 6†).
The next control investigated the fate of an indomethacin
drug NP in a solvent mixing simulation in the absence of the
polymer. In an attempt to replicate the expected experimental
aqueous phase where indomethacin nanoparticles would be in
a suspension, a 5 nm diameter amorphous indomethacin NP
was placed in the aqueous region of the biphasic box while the
acetone region was polymer-free. The simulation ran for a total
of 100 ns. The drug NP stayed intact until 70 ns while aer that
it started to slowly swell up and dissolve, due to the increasing
concentration of acetone around it (ESI Fig. 7†).
Following the rationale of the previous simulations, the
complete system comprised of both the indomethacin aqueous
suspension phase (a cubic solvated box with the 5 nm diameter
amorphous indomethacin NP in the centre) and the polymer-
rich organic phase (31 mPEG350-b-PCL2000 polymer chains
dispersed in acetone). The simulation box contained more thanRSC Adv., 2020, 10, 19521–19533 | 19525
Fig. 2 (Left) MD simulations for the formation of polymeric NPs,
where the polymer chains (mPEG: light blue, PCL: dark blue) are in the
organic phase (acetone: pink). Acetone mixes with water (not shown
for clarity) during phase 1 and is then removed during phase 2 tomimic
the evaporation that occurs in the experimental environment. (Right)

























































































View Article Online2.6 million atoms (Fig. 3). The simulation ran for 281 ns (phase
1, ESI Fig. 8†), followed by 5 simulation sets of 10 ns each, to
mimic the evaporation of the acetone (phase 2, ESI Fig. 9†),
resulting in a total simulation time of 330 ns. As the acetone and
water molecules began to mix, the polymer chains in the
acetone region started to aggregate, while the drug NP diffused
around the water region but stayed intact. However, at around
100 ns the drug NP encountered the nascently aggregating
polymer and dissolved in it. In order to identify the exact time
point where the interactions between the polymer chains and
the indomethacin NP occurred, the number of contacts, the
distance between the PCL blocks and the indomethacin mole-
cules as well as the radius of gyration and end-to-end distances
of the polymer chains were calculated (ESI Fig. 10 and 11†). The
complete dissolution of the indomethacin NP was not observedFig. 3 MD simulation for the formation of a polymer-coated indo-
methacin NP (colour scheme as in Fig. 2) (Top) phase 1 for the simu-
lation where the two regions, acetone and polymer on the left and
water and indomethacin on the right side, are allowed to mix freely. As
the indomethacin NP reaches in close proximity with the polymer
chains it is dissolved. The indomethacin molecules are then interacting
freely with the polymer chains for 150 ns. (Bottom) Phase 2 of the
simulation process where every 10 ns acetone molecules are replaced
with water molecules, mimicking acetone evaporation and thus
facilitating the self-assembly of the polymer–drug NP. The final NP is
seen as dissolved indomethacin molecules in a polymer matrix.
19526 | RSC Adv., 2020, 10, 19521–19533during the control simulation (acetone, no polymer) and thus
suggests that there is a synergistic effect between the polymer
and the acetone that breaks down the drug NP. At the same
time, as both the indomethacin NP and the polymer chains are
soluble in acetone, and the acetone is still present, the forma-
tion of a dense polymer–drug NP is inhibited. Once the acetone
molecules started to be replaced by water molecules the poly-
mers and drug particles started to interact strongly and
a particle started to form; a polymer–drug NP of 7 nm in
diameter was obtained. This resulting NP, aer nearly 330 ns of
simulation, did not resemble the ideal coated NP as envisioned
in the Introduction of this paper. The mPEG chains were
entangled with the drug molecules and since the drug NP had
dissolved completely during the rst 110 ns of the simulation,
the drugmolecules were dispersed uniformly inside the NP. The
polymer chains incorporated 144 indomethacin molecules
resulting in a 99.3% yield with respect to the drug. Only one
indomethacin molecule (0.69%) remained unattached to the
polymer–drug NP and was moving freely in water.
Experimental
Polymer characterisation
The polymers were synthesised as described in the methods
section employing a simple solvent-free ROP synthetic strategy.
The chain propagation and formation of mPEG-b-PCL diblock
copolymers was studied via 1H NMR. The proton signal at d 4.2–
4.27 ppm corresponding to the CH2methylene protons adjacent
to the ester bond to the PCL component was used for the
calculation of the degree of polymerization (DP). The molecular
weight of the polymer was calculated by the integration of peak
c aer setting peak b to the unit of 1, i.e. following the equation:
Mn(NMR) ¼ Mn(mPEG) + 114.14  DP (4)
The two triplets in the region 3.2–3.3 ppm correspond to the
catalyst TBD and were absent aer the purication by precipi-
tation in cold methanol (ESI Fig. 12†). The properties of the
polymers aer their characterisation via NMR and GPC are
summarised in Table 1 (ESI Fig. 13–16, ATR-IR in ESI Fig. 17†).
The hydrophobic segment of the polymers, experimentally
analysed, was very close to the targeted value of 2000 Da and for
this reason the polymers will be referred simply according to the
length of their mPEG chain. Further characterisation by DSC
(ESI Fig. 18–21† and contact angle (ESI Fig. 22†)) showed that
the increase of the hydrophilic mPEG block length resulted in
a decrease in the contact angle and a decrease of the PCL's
crystallinity (ESI Fig. 23†). Melting points of the polymers were
in the range of 50–59 C and no glass transition was detected for
any of the block copolymers, probably because these were likely
to fall below the minimum temperature of detection by the
adopted instrument83 (40 C).
Formation and characterisation of polymer nanoparticles
In order to distinguish the polymer-coated drug NPs from
polymer NPs, the formation of polymer micelles was investi-
gated for all the polymers.This journal is © The Royal Society of Chemistry 2020









mPEG350–PCL2000 1940 2290 7380 1.6 50.2 78.7
mPEG550–PCL2000 2060 2610 6820 1.6 55.7 82.3
mPEG750–PCL2000 1940 2690 7600 1.4 50.1 74
mPEG2000–PCL2000 2170 4170 10 960 1.5 59.1 82.5
mPEG350 390 1.2 6.8 49.1
mPEG550 680 1.1 14.4 129.6
mPEG750 980 1.1 29.7 145.4
mPEG2000 3300 1.1 51.9 171.7
3-CL 1.3 119.2
a Calculated by integration of peak b of the 1H NMR spectrum.

























































































View Article OnlineLarge particles that sedimented within 24 hours were formed
for the mPEG550PCL and mPEG750PCL polymers in the range 2–
1 mg (Fig. 4); this led to the decision to use polymer amounts in
the range of 2–1 mg for the rest of the polymers. In Fig. 4, the z-
average size (intensity distribution) and polydispersity data are
presented (bars and points respectively) for a range of different
polymer nanoparticle preparations from the four different
polymers using a range of different amounts of polymer.
Particles formed from mPEG350PCL demonstrated low poly-
dispersities, indicating that a well-dened NP population was
present. mPEG550PCL formed the largest NPs with diameters
more than 150 nm (with the exception of 0.1 mg where a 100 nm
z-average size was recorded). It also showed single peaks of NPs
with PDIs less than 0.2 with the exception of the NPs formed at
1 mg polymer, which precipitated upon the removal of acetone.
Polymer mPEG750PCL formed NPs of less than 100 nm in
diameter but the increased PDI values (between 0.30–0.38) in
the lower concentrations suggested sub-optimal stability. AsFig. 4 Left Y-axis: size (intensity) of the polymeric nanoparticles using
various polymer amounts (bars) for each different polymer. Error bars
represent the standard deviation of three measurements on a single
batch. Right Y-axis: PDI of measurements (symbols).
This journal is © The Royal Society of Chemistry 2020expected, due to the increased mPEG length and thus its steric
stabilisation properties, mPEG2000PCL demonstrated the
smallest range of NP size with the differing polymer amounts,
showing sizes ranging from 80 nm (0.2 mg) down to 50 nm (1.0
mg) in diameter. The reproducibility of the method was
demonstrated by preparation of 4 batches of themPEG350PCL at
0.1 mg of polymer which successfully replicated the same size
distribution via DLS (ESI Fig. 24†).
Zeta potential measurements were performed to evaluate the
surface potential of the polymer NPs (ESI Fig. 25†). All the
polymer NPs with the exception of mPEG750PCL (16.1 mV)
demonstrated zeta potential values lower than 20 mV. Zeta
potential values less than |30| mV suggest borderline unstable
behaviour84 for NP populations whose stability depends on
electrostatic forces. However, the polymer NPs produced in this
work were expected to be sterically stabilised to varying extents
relating to the length of the hydrophilic mPEG block.
In order to evaluate the NP stability further, a salt concen-
tration test was performed using barium chloride (BaCl2); the
increase in the ionic strength of the solution destabilises both
electrostatic and sterically stabilised particles, causing the
precipitation of unstable populations. For the NPs produced
with the lowest polymer amount (0.1 mg), the polymer NPs
started precipitating when the salt molarity reached 0.66 M (as
judged visually), indicating a stable population of NPs. The
physical stabilities of the NPs were also assessed. When kept
under typical lab conditions (stored in a cupboard at room
temperature), the NPs exhibited the same particle distribution
aer 1 month (ESI Fig. 26†). TEM was also used to characterise
the polymeric NPs. (ESI Fig. 27†).
Preparation of the indomethacin-bearing aqueous phase
Initial experiments evaluated both nanomilling and cryomilling
as possible methodologies for producing nanoparticle drug
suspensions, but these were less convenient and provided no
advantages compared to a simple sonication of crystalline
indomethacin (DSC at ESI Fig. 28†) in water for the preparation
of an aqueous suspension of drug. DLS measurements just
before the start of the coating process revealed a population of
sub-micron particles with an average diameter of 712 (357) nm
and a high polydispersity, indicative of the instability of the
suspension, which had a tendency to form large aggregates at
the surface of the water and precipitate in a timeframe of 2
hours (ESI Fig. 29†). Further analysis of the suspension by TEM
(Fig. 6A) and polarising optical microscopy (ESI Fig. 30†)
showed large aggregates with clear, sharp crystal planes. These
suspensions were used in the interfacial deposition as the
aqueous drug-rich phase.
Formation and characterisation of polymer-coated drug
nanoparticles
When the coating method was performed with mPEG350PCL
(0.1 mg) in the presence of the white, opaque drug suspension
(1 mg ml1), ne translucent nanosuspensions were formed
(ESI Fig. 31 and 32†) that had different size distributions when
compared to their drug-free polymer NP equivalents. The sameRSC Adv., 2020, 10, 19521–19533 | 19527
Fig. 6 (A) DLS results of polymer–drug NPs for the 0.1 mg polymer
amount. Bars represent the hydrodynamic diameter (left y axis) while
circles represent the PDI (right y-axis). (B) TEM picture of indomethacin
uncoated crystals. Scale bar 2000 nm. (C) TEM picture of mPEG350–
PCL coated indomethacin crystals (lowest starting polymer concen-
























































































View Article Onlinebehaviour was observed for all the different polymer amounts
selected and for all the polymers as well. With time, some larger
particles appeared due to a small amount of uncoated drug
nanoparticles which aggregated. These aggregates could be
easily removed using a short centrifugation which resulted in
the improvement of the PDI of the DLS measurements (ESI
Fig. 33†) and drug aggregates were not detectable by Polarised
Optical Microscopy (ESI Fig. 34†). DLS analysis for the highest
polymer amount (2 mg) is shown in Fig. 5 where the nearly
micrometre sized population of drug particles (red) has dis-
appeared and a single NP peak of polymer coated drug nano-
particles was obtained (diameter of 250 nm, blue peak in Fig. 5).
As illustrated in Fig. 6, all the polymers (0.1 mg polymer)
resulted in the formation of polymer-coated indomethacin NPs
with sizes in the range of 150–260 nm. However larger PDIs for
the mPEG750PCL and mPEG2000PCL led to focusing the future
experimental work on mPEG350PCL and mPEG550PCL coated
drug NPs. TEM was employed to visualise the polymer-coated
drug NPs (Fig. 6C) where it is clear that the coated NPs differ
signicantly from the starting indomethacin suspension
(Fig. 6B) both in size and in morphology as they are smaller and
do not exhibit the same sharp crystal edges. Although they
appear as if they have aggregated, this may be at least partially
due to the TEM sample preparation method.71,85 When larger
amounts of polymer were used (mPEG350PCL 2 mg) the
surrounding polymer coating was signicantly thicker (ESI
Fig. 35†). Preparation of 5 batches of PEG350PCL-coated indo-
methacin NPs resulted in the same size distribution by DLS (ESI
Fig. 36†) demonstrating the reproducibility of the procedure.
The suspensions were stable kept under typical lab conditions
for at least 10 days (ESI Fig. 37†).
Different starting concentrations of indomethacin (0.1, 0.25,
0.5 and 1mgml1 in water) were also investigated (ESI Fig. 38†);
although no apparent trend was observed, decrease of the drug
amount resulted in increase of the populations' PDI. Drug
loading and yield of the method using UV-Vis showed that drug
loading reached up to 78% for mPEG350PCL at 0.1 mg (ESI Table
1†), which is very high compared to the traditional batchFig. 5 Overlay of 3 separate DLS measurements of nanoparticles
produced using the highest amount of polymer (2 mg). The peak
corresponding to the polymer-coated drug NPs (blue) is shown in
comparison with those of the starting indomethacin population (red)
and the polymeric NP (green – dashed). This analysis was carried out
using polymer coated drug nanoparticles which had been centrifuged
to remove aggregated uncoated drug NP.
19528 | RSC Adv., 2020, 10, 19521–19533preparation methods for matrix nanoparticles (<25% (ref. 86)).
Similar results were found for the other polymers as well when
0.1 mg was used as the polymer in acetone concentration
(PEG750PCL 77.96%, PEG2000PCL 72.06%, data not shown).
Drug entrapment efficiency was initially calculated by the
conventional route of comparing the amount of encapsulated
drug recovered compared to the initial amount of drug (eqn (2),
ESI Table 1†). However, this gave exceptionally low drug
encapsulation. Since it was clear that there was signicant
mechanical loss of indomethacin from the aqueous stream
throughout the mixing apparatus, a control experiment was run
without polymer present in the acetone stream, and the amount
of drug recovered from the output determined. Consequently,
the entrapment efficiency was recalculated using the amount of
control drug recovered, instead of the starting amount of drug
to give more representative values for the entrapment efficiency
(eqn (3), ESI Table 1†).Discussion
There have been very many investigations into the formation of
polymer–drug nanoparticles via ‘nanoprecipitation’ methods
but rather fewer involving drug dispersions with amphiphilic
polymer coatings.33,36,87,88 Accordingly, at the outset of this work
there were a number of critical questions relating to the
mechanisms by which polymer-coated drug nanoparticles
might form. We thus decided to pursue a parallel course of
experimental and in silico work in order to understand the
processes and limitations of the polymer-coating method for
























































































View Article OnlineIn a typical nanoprecipitation method, the solute is dis-
solved in the presence of a stabilising molecule (i.e. polymer) in
a favourable solvent, which is then added into a miscible
solvent that acts as a non-solvent for both the solute and the
stabiliser.33 In the case of ash nanoprecipitation (FNP),35 this is
done by mixing the two streams in a conned space providing
supersaturation conditions in order for both the solute and the
stabiliser to precipitate simultaneously. This method has been
used to produce b-carotene–PEG–PCL,89 itraconazole–polox-
amer 407,82 and other polymer NPs.90 The nal NP population is
dependent on the solvent miscibility and molar ratios, the
nature and the length of the hydrophobic and hydrophilic
blocks of the polymeric stabilisers, as well as the mixing times
and ow ratios. However in this work, the FNP was adapted to
a pre-existing coating method (interfacial deposition9) where, in
the former case, iron oxide nanoparticles were present in the
aqueous environment.57 In comparison with existing NP
formulation techniques, the present method utilised both
bottom-up and top-down characteristics. The drug underwent
comminution by sonication while a ow nanoprecipitation
method was used to coat the NPs with polymer.Molecular dynamics computational aspects
Acetone is generally considered to be a safe solvent option easily
removed from formulations and at the same time it is miscible
with water at all molar fractions. The selection of the solvent is
a non-trivial issue; water-solvent miscibility affects the size of
the polymer NPS formed via solvent displacement methods,91
but it also affects the API solubility in the binary systems.92
From the modelling perspective of this work, the absence of an
accurate acetone model has proven to be a challenge, however,
whilst acknowledging the limitations of the acetone model
used, the physical representation of the system from the
simulations is satisfactory; the simulations reproduced the ex-
pected experimental behaviour of the pure systems i.e. the
dispersive behaviour of the mPEG-b-PCL polymers and the
behaviour of indomethacin NP in pure solvents. The previously
reported solvent clustering around the PCL chains that inhibits
their full aggregation43 was also observed in the present
simulations.
During the mixing of the solvents in the presence of both the
polymers and the drug NP, the water insoluble indomethacin
NP remained intact for the rst 100 ns. However, when the drug
NP diffused to be in close proximity to the polymer chains it was
dissolved by them, individual indomethacin molecules
diffusing freely amongst and interacting dynamically with, the
polymer chains for more than 150 ns. The dissolution also
appeared to be facilitated by the constant presence of acetone
molecules around the polymers. These observations, many of
which were unexpected, demonstrate the power of MD simu-
lations as a complement to experimental studies of interfacial
deposition, providing microscopic insights into macroscopic
behaviours. From a NP preparation perspective, this is the rst
time an unbiased all-atom MD simulation has resulted in the
self-assembly of a polymer–drug NP, something that reportedly
was missing from the eld.93 Past work on solvent displacementThis journal is © The Royal Society of Chemistry 2020processes via computational uid dynamics (CFD)42,44,94,95 have
provided invaluable information on parameters like solvents'
velocities, molar fractions, and mixer geometries, and are able
to predict the nal NP size based on population balance equa-
tions. However, such methods cannot describe the internal
morphology of the NPs. The NPs formed in this work are not
covalently bonded; the individual polymers and drug molecules
are dynamic, and in this case, this seems to be a vital aspect of
their properties and behaviour.Experimental aspects
At the outset of this work we were hoping that the thin polymer
coatings obtained using iron oxide nanoparticles57 could be
replicated on drug nanoparticles but had signicant concerns
that the solubility of drug in solvent or different physicochem-
ical properties of the drug and polymer used could adversely
affect the outcome. In practice, experimentally quite similar
outcomes were in fact obtained in these two pieces of work.
Polymer nanoparticles of small size (mean 100 nm) were
obtained in the ow solvent displacement production, however,
there was quite a broad dispersity of sizes dependent on the
amount of polymer used and PEG chain length of the polymers
involved. This is the sort of size range expected due to the low
amount of polymer used. When the solvent displacement
process was used in the coating procedure, an unexpected
observation was the production of a transparent suspension of
coated nanoparticles, with a much smaller NP size for the
polymer coated nanoparticles than the starting drug nano-
particles. From the microscopy results (both POM and TEM), it
can be seen that the drug particles are aggregates of many
smaller particles, however, the polymer coated nanoparticles
have a coating mainly around individual nanoparticles rather
than the whole aggregate. This suggests that under the condi-
tions of the coating procedure, the drug nanoparticles disag-
gregate and are coated, individually. As the TEM pictures of the
polymer coated drug NP aggregates show a larger size than the
DLS results, this suggests that some re-aggregation of the
polymer coated drug nanoparticles occurs, particularly in the
preparation of the TEM samples. This explanation is also sup-
ported by the computational studies which show that the
polymer dissolves the surface of the drug particle in forming the
drug coated nanoparticle, whichmay help in the process of drug
nanoparticle disaggregation. Overall the size of the coated drug
nanoparticles is clearly distinguishable from populations of
both polymer nanoparticles and uncoated drug nanoparticles.
Again, from the microscopy, the polymer appeared to be in
an even distribution on the drug nanoparticles, with no obvious
polymer nanoparticles present. However, the appearance of
small aggregates with time suggested that some uncoated drug
NP may be present, but once these drug aggregates were
centrifuged away, the resulting polymer coating suspensions
were stable with time. Experiments attempting to optimise the
polymer coated drug nanoparticle size by changing the
concentration of the drug present in the syringes did not show
an obvious relationship between drug concentration and nal
nanoparticle size, and it is likely that a range of parametersRSC Adv., 2020, 10, 19521–19533 | 19529
Fig. 7 Interpretation of the phenomena that take place during the
modified interfacial deposition. A population of micron-sized indo-
methacin particles in an aqueous environment is exposed to a flow of
polymer and acetone. The drug particles are either broken down or
dissolved due to the synergistic effect of the acetone and the poly-
mers. The polymers are able to coat the surface of the drug NPs,
making a population that can be stable due to steric interactions, while
the rest of the uncoated drug particles aggregate and finally precipitate
























































































View Article Onlineinuenced this outcome. As the amount of drug is decreased,
the relative ratio of polymer to drug will increase, thus it would
be expected that particle size would increase due to an
increased polymer coating thickness as seen with the decrease
of drug concentration from 1.0 to 0.5 mgml1. Alternatively it is
possible that, an increase in the polymer to drug ratio might
enhance the dissolution of the drug in the polymer leading to
a greater breakdown/separation of the drug particles leading to
a population of smaller drug particles. This mechanism may
account for the decrease in particle size seen with the decrease
in drug concentration from 0.5 to 0.1 mg ml1. Further exper-
iments and analysis would be needed to conrm these possi-
bilities. The stability of the drug coated nanoparticles over
a period of 10 days has been shown (ESI Fig. 37†), and this
would be expected because of the colloidal stability of the
polymers as demonstrated by the colloidal stability of the
polymer nanoparticles to barium chloride solutions. The high
melting temperature and low Tg of the PCL block would also be
expected to result in physically stable nanoparticle coatings.Correlation of molecular dynamics and experimental aspects
The number of molecules that could be included in the simu-
lation was limited by the computational cost, but we could
approximately reproduce experimental concentrations of
components and component ratios. As a result, though the
absolute size of, for example, nanoparticles that spontaneously
formed during the simulations could only be approximately 3%
as large as those observed in experiments, the processes
observed that lead to their formation could be realistic. In
particular, the observation that in simulations the polymer does
not somuch coat the nascent nanoparticle, as form an amalgam
with it, help us propose a mechanism for what is observed
experimentally.
In an attempt to interpret the interactions that take place
based on the information collected from both the experimental
and the computational studies, a graphical illustration is pre-
sented in Fig. 7. Micron-sized indomethacin particles are
present in the aqueous phase. Once exposed under ow to
acetone and polymers, their fate depends on their initial size:
larger particles will have their surface dissolved, while smaller
particles will dissolve completely to indomethacin molecules.
This size reduction is not solely due to the presence of the
acetone as the MD simulations have demonstrated that the
polymers dissolve the indomethacin NPs as well. Also, in the
light of the morphology of the polymer–drug NP as shown by
MD, it is plausible to assume that with the larger drug nano-
particles used experimentally, the polymers could form a satu-
rated surface, where polymer chains are entangled with
dispersed indomethacin molecules, while the core of the drug
NP remains crystalline.
It may be expected that some polymer micellisation may
occur independently from the coating of the drug nano-
particles. The absence of a second size peak in the DLS
measurements indicates that there was a preference for coating
of the nanoparticle surface. This may depend on the existence19530 | RSC Adv., 2020, 10, 19521–19533of some polymer drug compatibility as has previously been
suggested in polymer coating of iron oxide nanoparticles.
In the nal nanosuspension, the nanosized indomethacin
particles are polymer-coated and thus sterically stable. On the
contrary, the uncoated indomethacin molecules or particles
without the steric stabilisation will form larger aggregates that
can be separated from the coated population by centrifugation.
We believe the presented work could aid the design and
formulation of poorly soluble drugs. Polymer coated drug
nanoparticles have an intrinsic advantage compared to matrix
type nanoparticles as a result of the inherently higher drug
loadings, even though these are dependent on how thin the
polymer coated drug layer can be produced and/or how thick it
needs to be to full its delivery function. The very high drug
loadings (over 75% w/w) already shown, lead to the possibilities
for a much wider range of usages for drug nanoparticles in oral,
parenteral or for other routes of delivery. The presence of
a polymer coating on the drug nanoparticle has the advantage
of providing colloidal stability compared to pure drug nano-
particles, and also that the surface coating then becomes
dependent on the properties of the polymer rather than the
drug. This method of polymer coating also has the advantage of
not requiring high amounts of surfactant which can have
several disadvantages in certain formulations. These advan-
tages may give opportunities in common procedures for
formulating nanoparticles, where previously the formulation of
a number of different drugs depended on the surface crystal
characteristics of the individual drugs. The methodology is very
simple and reproducible from readily available materials and
can be readily converted to a ow process method, making this
methodology potentially attractive to pharmaceutical industry.
All these characteristics add up to a wide range of possibilities
across many different possible formulation areas.Conclusions
This work has combined both theoretical and practical
approaches to investigate the formation of polymer-coated drug
























































































View Article Onlinethat producedmPEG-b-PCL coated indomethacin NPs with high
drug loadings. In parallel, all-atom MD simulations of the
nanoprecipitation method were performed, and provided
a hypothesis to explain the experimental observations. We
suggest that the combination of both aspects of the pharma-
ceutical eld can provide a nanoformulation-by-design approach;
using computational techniques in parallel with ‘wet-lab’
experimental work in order to understand and design better
formulations.Conflicts of interest
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